Abstract: A method for the topical treatment of skin affected with acne, rosacea, or a combination thereof. Sodium chloride in a substantially pure form is topically applied to the affected skin by gently gliding the sodium chloride over the affected skin in a manner insufficient to cause abrasion and debridement of the affected skin. A solid block of about 98% to about 100% by weight sodium chloride free of a carrier and/or free of other topical acne-treatment medicaments and/or free of other topical rosacea-treatment medicaments should be used. The applied sodium chloride is left on the skin. Preferably, the affected skin is pre-moistened with water from shaving, bathing, splashing water on the skin, and the like prior to gliding the sodium chloride thereon.

Abstract: A method and compound having betamethasone dipropionate and all-trans-retinoic is disclosed for the treatment of hair loss. The method also includes identifying any underlying conditions causing hair loss and administration of a salve of betamethasone dipropionate and all-trans-retinoic acid to the affected areas.

Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds that are antagonists of the progesterone receptor having the general structure: wherein: R1, and R2 are chosen independently from each other from H, OH; OAc; alkylaryl; alkylheteroaryl; 1-propynyl; 3-propynyl; and optionally substituted alkyl, O(alkyl); aryl; or heteroaryl groups; or R1 and R2 are joined to FORM a ring comprising —CH2(CH2)nCH2— where n=0-5; —CH2CH2CMe2CH2CH2—; —O(CH2)mCH2— where m=1-4; O(CH2)pO— where p=1-4; —CH2CH2OCH2CH2—; —CH2CH2N(H or alkyl)CH2CH2—; or R1, and R2 together comprise a double bond to CMe2; C(cycloalkyl), O, or C(cycloether); R3 is H, OH, NH2, CORA; or optionally substituted alkenyl or alkynyl groups; RA=H or optionally substituted alkyl, alkoxy, or aminoalkyl groups; R4=H, halo, CN, NH2, or optionally substituted alkyl, alkoxy, or amino

Abstract: This invention relates to cyclic combination therapies utilizing, in combination with a progestin, an estrogen, or both, progesterone receptor antagonists of the general structure: wherein the substituents are as defined herein, or pharmaceutically acceptable salt thereof.

Abstract: Novel spermicidal compounds which are organometallic cyclopentadienyl metal complexes, particularly vanadium IV complexes, are described including corresponding contraceptive and therapeutic compositions and method for providing contraception and selective killing of testicular germ cells. Included among the vanadium complexes are vanadocene dichloride, vanadocene dibromide, bis (methyl cyclopentadienyl) vanadium dichloride, vanadocene diiodide, vanadocene di-pseudobalides, and others. Most active found was vanadocene diselenocyanate.

Abstract: This invention provides pharmaceutical uses for 2&agr;-methyl-19-nor-20(S)-1&agr;, 25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. This compound also increases both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.

Abstract: In one embodiment, the present invention discloses a method and pharmaceutical composition for lowering serum cholesterol in a patient. The method comprises administering to the patient a pharmaceutical composition comprising a therapeutically effective cholesterol lowering amount of an imidazole.

Abstract: A feed composition for animals (livestock, poultry, fish or pet) which contains poly-&ggr;-glutamic acid (and/or degradated product thereof) and, a method for reducing body fat acumulation in animals which comprises feeding animals with a feed composition containing poly-&ggr;-glutamic acid.

Abstract: The present invention relates to a method of feeding carnitine supplemented diets to sows during the period of gestation or during both gestation and lactation periods. The method enhances pork productivity by increasing litter and pig birth and weaning weights, reducing the number of stillborn pigs and increasing the number of pigs born alive in the subsequent reproductive cycle. Sow diets of this invention include carnitine, such as L-carnitine or L-carnitine salts. Carnitine is generally added to the swine feed formulation in the amount of from about 50 to about 5,000 ppm.

Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: wherein R, R′, R1, R′1, R2, R′2, R3, R′3, R4, R′4, R5, R′5, R6, R′6, R7, R′7, R8, R′8, R9, R′10, R10 and R′10, X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, myocardial infarction, stroke, atherosclerosis, and all other conditions of oxidant-induced tissue damage or injury.

Abstract: Methods of using the chromium(III) complex represented by the formula [Cr3O(O2CCH2CH3)6(H2O)3]+ as a nutritional supplement.

Abstract: The claims define a method which is based on the use of baclofen to suppress the cough of a patient who is afflicted with a cough that is induced by the administration of an ACE inhibitor. The usual dose of baclofen is from 10 to 30 mg daily. A pharmaceutical composition which comprises an effective amount of an ACE inhibitor is also disclosed which is a combination of an ACE inhibitor and an amount of baclofen which is effective to suppress the cough which is caused by the administration of the therapeutic dose of an ACE inhibitor.

Abstract: Compositions, medicaments, and methods for the promotion of hair growth are disclosed. These compositions and medicaments are comprised of either local anesthetics of the secondary or tertiary amino type or niacin. The preferred secondary and tertiary amino compounds include those which are esters of para-aminobenzoic acid, esters of benzoic acid, esters of meta-amino benzoic acid, amides, ethers, and ketones. The preferred compositions and medicaments include either procaine hydrochloride or niacin or procaine hydrochloride and niacin in a non-sulfur-containing carrier. The disclosed compositions and medicaments may be topically applied to a scalp in need thereof by an eyedropper or other suitable means. An improved embodiment of this application adds minoxidil.

Abstract: An aqueous or aqueous/alcoholic cosmetic composition which can be sprayed, comprising an aqueous dispersion of insoluble film-forming polymer particles and at least one insoluble silicone, wherein the polymer particles are present in a concentration greater than 15%, relative to the total weight of the composition, and further wherein the glass transition temperature of the insoluble polymer particles ranges from 15 to 35.degree. C. The invention also relates to a process for the cosmetic treatment of keratinous substances using these compositions and to the use of the silicone for improving the quality of the spraying of the composition.

Abstract: A kit which is adapted and designed to provide both data on the current reproductive status of a patient, and contraception for those who are not pregnant, but recently engaged in unprotected sex.

Abstract: The present invention provides an improved method for treating vulvar vestibulitis in a patient, comprising applying to the vestibule or the vestibule and the vagina of a patient an effective amount of a composition comprising a compound which inhibits the release of mediators from mast cells. The method is simple, inexpensive, well tolerated, and effective in the majority of cases.

Abstract: Method of treating or preventing osteoporosis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form increases vitamin D blood level without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.

Abstract: Method of treating psoriasis by administering orally a 1.alpha.-hydroxyprevitamin D. This previtamin D form treats psoriasis without significant risk of hypercalcemia associated with other oral dosing of vitamin D forms. The 1.alpha.-hydroxyprevitamin is compounded into a pharmaceutical composition in combination with a pharmaceutically acceptable excipient.

Abstract: The use of (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-p yrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, (3S 6R,12aR)-2,3,6,7,12,12a-hexahydro-2,3-dimethyl-6-(3,4-methylenedioxyhenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione, and physiologically acceptable salts and solvates thereof, in methods and compositions for the treatment of impotence.

Abstract: The combination preparation for contraception includes a first stage of 2 to 4 first stage daily dosage portions, a second stage of two groups of second stage daily dosage portions, a third stage of 2 to 4 third stage daily dosage portions and an additional stage of 2 to 4 additional stage daily dosage portions. The first stage daily dosage portion is an effective amount of natural estrogen, the second stage daily dosage portion is an effective amount of a combination of natural estrogen and natural or synthetic gestogen, the third stage daily dosage portion is another effective amount of natural estrogen and an additional stage daily dosage portion consists of a placebo. The first group of the second stage consists of 3 to 5 daily dosage portions and the second group, 13 to 17 daily dosage portions. More of the gestogen is included in the effective amount in the second group of the second stage than in the first group.